91 related articles for article (PubMed ID: 32376721)
1. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.
Cham J; Zhang L; Kwek S; Paciorek A; He T; Fong G; Oh DY; Fong L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376721
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
3. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).
Pachynski RK; Morishima C; Szmulewitz R; Harshman L; Appleman L; Monk P; Bitting RL; Kucuk O; Millard F; Seigne JD; Fling SP; Maecker HT; Duault C; Ramchurren N; Hess B; D'Amico L; Lacroix A; Kaiser JC; Morre M; Grégoire A; Cheever M; Yu EY; Fong L
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452927
[TBL] [Abstract][Full Text] [Related]
4. C reactive protein impairs adaptive immunity in immune cells of patients with melanoma.
Yoshida T; Ichikawa J; Giuroiu I; Laino AS; Hao Y; Krogsgaard M; Vassallo M; Woods DM; Stephen Hodi F; Weber J
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303612
[TBL] [Abstract][Full Text] [Related]
5. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients.
Subrahmanyam PB; Dong Z; Gusenleitner D; Giobbie-Hurder A; Severgnini M; Zhou J; Manos M; Eastman LM; Maecker HT; Hodi FS
J Immunother Cancer; 2018 Mar; 6(1):18. PubMed ID: 29510697
[TBL] [Abstract][Full Text] [Related]
6. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.
Santegoets SJ; Stam AG; Lougheed SM; Gall H; Scholten PE; Reijm M; Jooss K; Sacks N; Hege K; Lowy I; Cuillerot JM; von Blomberg BM; Scheper RJ; van den Eertwegh AJ; Gerritsen WR; de Gruijl TD
Cancer Immunol Immunother; 2013 Feb; 62(2):245-56. PubMed ID: 22878899
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma.
Ray A; Williams MA; Meek SM; Bowen RC; Grossmann KF; Andtbacka RH; Bowles TL; Hyngstrom JR; Leachman SA; Grossman D; Bowen GM; Holmen SL; VanBrocklin MW; Suneja G; Khong HT
Oncotarget; 2016 Sep; 7(39):64390-64399. PubMed ID: 27391442
[TBL] [Abstract][Full Text] [Related]
8. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.
Kvistborg P; Philips D; Kelderman S; Hageman L; Ottensmeier C; Joseph-Pietras D; Welters MJ; van der Burg S; Kapiteijn E; Michielin O; Romano E; Linnemann C; Speiser D; Blank C; Haanen JB; Schumacher TN
Sci Transl Med; 2014 Sep; 6(254):254ra128. PubMed ID: 25232180
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?
Cha E; Small EJ
Cancer Med; 2013 Apr; 2(2):243-52. PubMed ID: 23634292
[TBL] [Abstract][Full Text] [Related]
10. Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients.
Cabel L; Loir E; Gravis G; Lavaud P; Massard C; Albiges L; Baciarello G; Loriot Y; Fizazi K
J Immunother Cancer; 2017; 5():31. PubMed ID: 28428880
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy induces responses of lung cancer to CTLA-4 blockade.
Formenti SC; Rudqvist NP; Golden E; Cooper B; Wennerberg E; Lhuillier C; Vanpouille-Box C; Friedman K; Ferrari de Andrade L; Wucherpfennig KW; Heguy A; Imai N; Gnjatic S; Emerson RO; Zhou XK; Zhang T; Chachoua A; Demaria S
Nat Med; 2018 Dec; 24(12):1845-1851. PubMed ID: 30397353
[TBL] [Abstract][Full Text] [Related]
12. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.
Yuan J; Page DB; Ku GY; Li Y; Mu Z; Ariyan C; Gallardo HF; Roman RA; Heine AI; Terzulli SL; Ritter E; Gnjatic S; Ritter G; Jungbluth AA; Allison JP; Old LJ; Wolchok JD
Cancer Immun; 2010 Jan; 10():1. PubMed ID: 20052966
[TBL] [Abstract][Full Text] [Related]
13. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Van Allen EM; Miao D; Schilling B; Shukla SA; Blank C; Zimmer L; Sucker A; Hillen U; Foppen MHG; Goldinger SM; Utikal J; Hassel JC; Weide B; Kaehler KC; Loquai C; Mohr P; Gutzmer R; Dummer R; Gabriel S; Wu CJ; Schadendorf D; Garraway LA
Science; 2015 Oct; 350(6257):207-211. PubMed ID: 26359337
[TBL] [Abstract][Full Text] [Related]
14. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.
Roszik J; Haydu LE; Hess KR; Oba J; Joon AY; Siroy AE; Karpinets TV; Stingo FC; Baladandayuthapani V; Tetzlaff MT; Wargo JA; Chen K; Forget MA; Haymaker CL; Chen JQ; Meric-Bernstam F; Eterovic AK; Shaw KR; Mills GB; Gershenwald JE; Radvanyi LG; Hwu P; Futreal PA; Gibbons DL; Lazar AJ; Bernatchez C; Davies MA; Woodman SE
BMC Med; 2016 Oct; 14(1):168. PubMed ID: 27776519
[TBL] [Abstract][Full Text] [Related]
15. T cell immune awakening in response to immunotherapy is age-dependent.
Salih Z; Banyard A; Tweedy J; Galvani E; Middlehurst P; Mills S; Weightman J; Gupta A; Lorigan PC; Zhou C; Dhomen N; Valpione S; Marais R
Eur J Cancer; 2022 Feb; 162():11-21. PubMed ID: 34952479
[TBL] [Abstract][Full Text] [Related]
16. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
Penter L; Zhang Y; Savell A; Huang T; Cieri N; Thrash EM; Kim-Schulze S; Jhaveri A; Fu J; Ranasinghe S; Li S; Zhang W; Hathaway ES; Nazzaro M; Kim HT; Chen H; Thurin M; Rodig SJ; Severgnini M; Cibulskis C; Gabriel S; Livak KJ; Cutler C; Antin JH; Nikiforow S; Koreth J; Ho VT; Armand P; Ritz J; Streicher H; Neuberg D; Hodi FS; Gnjatic S; Soiffer RJ; Liu XS; Davids MS; Bachireddy P; Wu CJ
Blood; 2021 Jun; 137(23):3212-3217. PubMed ID: 33720354
[TBL] [Abstract][Full Text] [Related]
17. Multistep tumor genetic evolution and changes in immunogenicity trigger immune-mediated disease eradication in stage IV melanoma: lessons from a single case.
Vallacchi V; Vergani E; Cossa M; Gargiuli C; Busico A; Devecchi A; Dugo M; Bergamaschi L; De Cecco L; Cavalieri S; Valeri B; Tamborini E; Gallino G; Del Vecchio M; Santinami M; Sensi M; Rivoltini L; Di Guardo L; Rodolfo M
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38177075
[TBL] [Abstract][Full Text] [Related]
18. γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer.
Frieling JS; Tordesillas L; Bustos XE; Ramello MC; Bishop RT; Cianne JE; Snedal SA; Li T; Lo CH; de la Iglesia J; Roselli E; Benzaïd I; Wang X; Kim Y; Lynch CC; Abate-Daga D
Sci Adv; 2023 May; 9(18):eadf0108. PubMed ID: 37134157
[TBL] [Abstract][Full Text] [Related]
19. Improved T-cell Receptor Diversity Estimates Associate with Survival and Response to Anti-PD-1 Therapy.
Bortone DS; Woodcock MG; Parker JS; Vincent BG
Cancer Immunol Res; 2021 Jan; 9(1):103-112. PubMed ID: 33177107
[TBL] [Abstract][Full Text] [Related]
20. Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy.
Valpione S; Galvani E; Tweedy J; Mundra PA; Banyard A; Middlehurst P; Barry J; Mills S; Salih Z; Weightman J; Gupta A; Gremel G; Baenke F; Dhomen N; Lorigan PC; Marais R
Nat Cancer; 2020 Feb; 1(2):210-221. PubMed ID: 32110781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
